Search Medical Condition
Please enter condition
Please choose location

Cleveland, Florida Clinical Trials

A listing of Cleveland, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (43) clinical trials

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07

This is an open-label, two- arm, extension study designed to enable subjects who have experienced radiologically- confirmed disease progression in Study IPI-145-07 to receive the alternative treatment (either IPI-145 or ofatumumab) than what was received during study IPI-145-07. Subjects who have previously received ofatumumab in study IPI-145-07 will receive a ...

Phase

4.38 miles

Learn More »

A Study to Evaluate the Efficacy Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

This is a multicenter, randomized, parallel-group, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of SEP-363856 flexibly dosed at 25, 50, or 75 mg/day for 6 weeks in male and female subjects ≥ 55 years of age with a clinical diagnosis of PDP. The study will randomize approximately 36 ...

Phase

4.38 miles

Learn More »

A Multicenter Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose "Wearing-Off"

Each patient will participate for up to 62 weeks, which includes a Screening Period, followed by a Baseline Visit and open-label treatment for 1 year with a safety Follow-up 4 weeks after the last treatment. - Screening Period: up to 6 weeks. - Open-Label Treatment Period: 52 weeks (1 year) ...

Phase

4.38 miles

Learn More »

A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes

This multi-center study will aim to evaluate the pharmacokinetics (PK) and comparative bioavailability of a single dose of APL-130277 sublingual thin film with subcutaneous (s.c.) APO-go® and s.c. APOKYN® in subjects with Parkinson's disease (PD). The dose of APOKYN® (≤ 5 mg) will be based on the subjects' current prescribed ...

Phase

4.38 miles

Learn More »

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

This is an event driven study to reach statistical power given all other assumptions. Subjects will visit the clinic 1 month after randomization and at regular intervals thereafter. Additionally, for any subject prematurely discontinuing study medication, assessments will be conducted every 6 months for the collection of study endpoints. Those ...

Phase

6.64 miles

Learn More »